AZD6703   Click here for help

GtoPdb Ligand ID: 7687

Synonyms: AZ 12012199 | AZ-12012199 | AZ12012199 | AZD 6703 | AZD-6703
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: AZD6703 is a potent, selective and reversible orally bioavailable inhibitor of p38 mitogen-activated protein kinase 14 (MAPK14).
This compound was in the AstraZeneca/MRC repurposing list from 2011.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 69.95
Molecular weight 417.22
XLogP 3.31
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CN1CCN(CC1)c1ccc2c(c1)c(=O)n(cn2)c1cc(ccc1C)C(=O)NC1CC1
Isomeric SMILES CN1CCN(CC1)c1ccc2c(c1)c(=O)n(cn2)c1cc(ccc1C)C(=O)NC1CC1
InChI InChI=1S/C24H27N5O2/c1-16-3-4-17(23(30)26-18-5-6-18)13-22(16)29-15-25-21-8-7-19(14-20(21)24(29)31)28-11-9-27(2)10-12-28/h3-4,7-8,13-15,18H,5-6,9-12H2,1-2H3,(H,26,30)
1. Brown DS, Cumming JG, Bethel P, Finlayson J, Gerhardt S, Nash I, Pauptit RA, Pike KG, Reid A, Snelson W et al.. (2012)
The discovery of N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin-3(4H)-yl]benzamide (AZD6703), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases.
Bioorg Med Chem Lett, 22 (12): 3879-83. [PMID:22608965]
2. Clark JE, Sarafraz N, Marber MS. (2007)
Potential of p38-MAPK inhibitors in the treatment of ischaemic heart disease.
Pharmacol Ther, 116 (2): 192-206. [PMID:17765316]
3. Saklatvala J. (2004)
The p38 MAP kinase pathway as a therapeutic target in inflammatory disease.
Curr Opin Pharmacol, 4 (4): 372-7. [PMID:15251131]
4. Schieven GL. (2005)
The biology of p38 kinase: a central role in inflammation.
Curr Top Med Chem, 5 (10): 921-8. [PMID:16178737]